OnKure Therapeutics (OKUR) Accumulated Expenses (2020 - 2026)

OnKure Therapeutics (OKUR) has 7 years of Accumulated Expenses data on file, last reported at $1.1 million in Q1 2026.

• Quarterly Accumulated Expenses fell 81.09% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 81.09% YoY) and the FY2025 annual result came in at $3.9 million, up 24.14% from the prior year.
• Accumulated Expenses fell to $1.1 million in Q1 2026, from $3.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $11.6 million in Q2 2023 to a low of $725000.0 in Q3 2024.
• A 5-year average of $4.9 million and a median of $4.7 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 691.92% — and 2024, when it slumped 93.27%.
• Tracing OKUR's Accumulated Expenses over 5 years: stood at $4.8 million in 2022, then retreated by 24.18% to $3.7 million in 2023, then declined by 13.31% to $3.2 million in 2024, then climbed by 24.14% to $3.9 million in 2025, then slumped by 71.69% to $1.1 million in 2026.
• The last three Accumulated Expenses figures came in at $1.1 million (Q1 2026), $3.9 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.